Actively Recruiting
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Led by SEED Therapeutics, Inc. · Updated on 2026-02-18
171
Participants Needed
6
Research Sites
213 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
CONDITIONS
Official Title
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older on the day of consent, except for adolescents 16 years or older with Ewing Sarcoma or other biologically relevant cancers
- Have a metastatic or locally advanced solid tumor that cannot be removed by surgery
- Have at least one measurable lesion or evaluable disease by RECIST v1.1 criteria
- ECOG performance status of 0, 1, or 2 at screening
- Have adequate organ function as defined in the study protocol
You will not qualify if you...
- Received radiotherapy within 2 weeks before treatment
- Have active central nervous system metastases or carcinomatous meningitis (except stable, treated brain metastases)
- Received any local or systemic anticancer therapy or investigational agent within 14 days or 5 half-lives, whichever is shorter
- Had major surgery within 28 days before starting study treatment
- Have unresolved toxicities from previous cancer treatments except hair loss and peripheral neuropathy
- Have previously been treated with an RBM39 inhibitor or degrader
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
The City of Hope National Medical Center
Duarte, California, United States, 91010
Actively Recruiting
2
Hoag Memorial Hospital
Newport Beach, California, United States, 92263
Actively Recruiting
3
Mass General Brigham Cancer Institute
Boston, Massachusetts, United States, 02114
Not Yet Recruiting
4
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
5
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
6
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
D
Dr. Eric Rowinsky Chief Medical Officer
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here